MicroRNAs: Powerful regulators and potential diagnostic tools in cardiovascular disease

Kardiologia Polska

Volumn 73, Issue 1, 2015, Pages 1-6

  Klimczak, Dominika ^a   Paczek, Leszek ^a   Jazdzewski, Krystian ^a,b   Kuch, Marek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BIOGENESIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL DEGENERATION; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENE FUNCTION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SYSTEMIC CIRCULATION; THROMBOCYTE FUNCTION; CARDIOVASCULAR DISEASES; METABOLISM;

CARDIOVASCULAR DISEASES; HUMANS; MICRORNAS;

EID: 84921683786     PISSN: 00229032     EISSN: 18974279     Source Type: Journal    
DOI: 10.5603/KP.a2014.0210     Document Type: Review

References (46)

1. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature, 2001; 409: 860-921.
2. Brown TA Genomes 2nd Ed. BIOS Scientific Publishers Ltd. Oxford, UK, 2002.
3. De Rosa SA, Curcio A, Indolfi C. Emerging role of microRNAs in cardiovascular diseases. Circ J, 2014; 78: 567-575.
4. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005; 120: 15-20.
5. Kozomara A, Griffiths-Jones S. miRBase: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res, 2014; 42 (Database issue): 25.
6. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res, 2012; 110: 483-495.
7. Zhang Y, Liu D, Chen X et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell, 2010; 39: 133-144.
8. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer, 2006; 6: 259-269.
9. Jazdzewski K, Boguslawska J, Jendrzejewski J et al. Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J Clin Endocrinol Metab, 2011; 96: 546-553.
10. Jazdzewski K, Murray EL, Franssila K et al. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA, 2008; 105: 7269-7274.
11. Jazdzewski K, Liyanarachchi S, Swierniak M et al. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci USA, 2009; 106: 1502-1505.
12. Gilad S, Meiri E, Yogev Y et al. Serum microRNAs are promising novel biomarkers. PLoS One, 2008; 3: 0003148.
13. Hergenreider E, Heydt S, Tréguer K et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol, 2012; 14: 249-256.
14. Santarpia L, Nicoloso M, Calin GA. MicroRNAs: A complex regulatory network drives the acquisition of malignant cell phenotype. Endocr Relat Cancer, 2010; 17: F51-F75.
15. Boon RA, Seeger T, Heydt S et al. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ Res, 2011; 109: 1115-1119.
16. Landry P, Plante I, Ouellet DL et al. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol, 2009; 16: 961-966.
17. Nagalla S, Shaw C, Kong X et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood, 2011 117: 5189-5197.
18. Wang GK1, Zhu JQ, Zhang JT et al. Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J, 2010; 31: 659-666.
19. Kulshreshtha R, Ferracin M, Wojcik SE et al. A microRNA signature of hypoxia. Mol Cell Biol, 2007; 27: 1859-1867.
20. Wang J, Yang X. The function of miRNA in cardiac hypertrophy. Cell Mol Life Sci, 2012; 69: 3561-3570.
21. Bang C, Batkai S, Dangwal S et al. Cardiac fibroblast-derived micro- RNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest, 2014; 124: 2136-2146.
22. Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol, 2008; 45: 185-192.
23. Haider BA, Baras AS, McCall MN et al. A critical evaluation of microRNA biomarkers in non-neoplastic disease. PLoS One, 2014; 9.
24. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA, 2008; 105: 10513-10518.
25. D'Alessandra Y, Devanna P, Limana F et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J, 2010; 31: 2765-2773.
26. Li YQ, Zhang MF, Wen HY et al. Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. Clinics (Sao Paulo), 2013; 68: 75-80.
27. Devaux Y, Vausort M, Goretti E et al. Use of circulating microRNAs to diagnose acute myocardial infarction. Clin Chem, 2012; 58: 559-567.
28. van Rooij E, Quiat D, Johnson BA et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell, 2009; 17: 662-673.
29. Olivieri F, Antonicelli R, Lorenzi M et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol, 2013; 167: 531-536.
30. Liu N, Olson JD. MicroRNA regulatory networks in cardiovascular development. Dev Cell, 2010; 18: 510-525.
31. Widera C, Gupta SK, Lorenzen JM et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol, 2011; 51: 872-875.
32. Guo M, Mao X, Ji Q et al. miR-146a in PBMCs modulates Th1 function in patients with acute coronary syndrome. Immunol Cell Biol, 2010; 88: 555-564.
33. Yao R, Ma Y, Du Y et al. The altered expression of inflammation-related microRNAs with microRNA-155 expression correlates with Th17 differentiation in patients with acute coronary syndrome. Cell Mol Immunol, 2011; 8: 486-495.
34. Hoekstra M, van der Lans CA, Halvorsen B et al. The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochem Biophys Res Commun, 2010; 394: 792-797.
35. Gao W, He HW, Wang ZM et al. Plasma levels of lipometabolism- related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis, 2012; 11: 11-55.
36. Tijsen AJ, Creemers EE, Moerland PD et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res, 2010; 106: 1035-1039.
37. Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation, 2007; 116: 258-267.
38. Fukushima Y, Nakanishi M, Nonogi H et al. Assessment of plasma miRNAs in congestive heart failure. Circ J, 2011; 75: 336-340.
39. Fichtlscherer S, De Rosa S, Fox H et al. Circulating microRNAs in patients with coronary artery disease. Circ Res, 2010; 107: 677-684.
40. Endo K, Naito Y, Ji X, Nakanishi M et al. MicroRNA 210 as a biomarker for congestive heart failure. Biol Pharm Bull, 2013; 36: 48-54.
41. Goren Y, Kushnir M, Zafrir B et al. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail, 2012; 14: 147-154.
42. van Rooij E, Marshall WS, Olson EN. Toward microRNA-based therapeutics for heart disease: The sense in antisense. Circ Res, 2008; 103: 919-928.
43. Condorelli G, Latronico MV, Cavarretta E. microRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol, 2014; 63: 2177-2187.
44. Gezer U, Keskin S, Igci A et al. Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy. Oncol Lett, 2014; 8: 845-848.
45. Moldovan L, Batte KE, Trgovcich J et al. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med, 2014; 18: 371-390.
46. van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med, 2014; 6: 851-864.